Compare Adaptive Biotechnologies Corp (ADPT) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Norwegian Cruise Line Holdings Ltd — how do they compare? Adaptive Biotechnologies Corp trades at $19.85 (market cap $3.33B), while Norwegian Cruise Line Holdings Ltd trades at $18.39 (market cap $8.65B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 2.6× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| ADPT | NCLH | |
|---|---|---|
Market Cap | $3.33B | $8.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $26.94 |
52-Week Low | $10.24 | $14.79 |
Enterprise Value | $3.19B | $23.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
NCLH trades at $18.83, down 4.8% on the day, reflecting near-term pressure amid a bearish technical signal. The company has demonstrated consistent earnings beats, with Q1 2026 EPS of $0.23 exceeding the $0.15 estimate. Fundamentals show a P/E of 15.53 and a net income margin of 5.66%, while recent news highlights new executive appointments and future cruise itineraries. The stock is trading below the consensus analyst price target of $22.00.
The outlook is mixed; strong earnings performance and a favorable valuation offer upside potential, but high debt levels and a bearish technical trend present significant risks. The stock's performance is closely tied to travel demand and macroeconomic factors affecting the cruise industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
